OrphAI Therapeutics ^Company

At OrphAI Therapeutics, we are focused on identifying and developing treatments for rare orphan conditions. Our current clinical stage drug candidates target several orphan disorders including amyotrophic lateral sclerosis (ALS), pulmonary arterial hypertension (PAH) pulmonary sarcoidosis, and bronchiolitis obliterans syndrome (BOS) post lung transplant.